甲磺酸阿帕替尼联合多西他赛二线治疗晚期胃癌的临床研究  

Summary of clinical research progression of apatinib combined with docetaxel in second-line treatment of advanced gastric cancer

作　　者：杨牡丹[1] 高峻[1] 刘晓玲[1] 杨文慧[1] 卢宏霞[1] Yang Mudan;Gao Jun;Liu Xiaoling;Yang Wenhui;Lu Hongxia(The Second Department of Digestive Oncology,Shanxi Tumor Hospital,Taiyuan 030013,China)

机构地区：[1]山西省肿瘤医院消化二科,太原030013

出　　处：《中华肿瘤杂志》2020年第7期594-597,共4页Chinese Journal of Oncology

摘　　要：目的:分析甲磺酸阿帕替尼联合多西他赛治疗一线化疗失败后晚期胃癌患者的近期疗效及安全性。方法:收集2017年3月至2018年5月就诊于山西省肿瘤医院、采用一线化疗方案(非多西他赛或紫杉醇)治疗失败后的23例晚期胃癌患者的临床资料,给予阿帕替尼联合多西他赛治疗,分析患者的近期疗效和安全性。结果:23例患者中,20例患者可评价疗效,其中部分缓解4例,稳定13例,疾病进展3例;客观缓解率为20.0%,疾病控制率为85.0%,中位无进展生存时间为4.5个月。不良反应以高血压、呕吐和乏力为主。结论:阿帕替尼联合多西他赛二线治疗晚期胃癌患者具有生存获益,安全性良好。Objective To investigate the progression-free survival(PFS)and safety of apatinib combined with docetaxel treated patients with advanced gastric cancer after failure of first-line chemotherapy.Methods From March 2017 to May 2018,23 patients with advanced gastric cancer who had received a failure of first-line chemotherapy(either fedocetaxel or paclitaxel)were treated with apatinib combined with docetaxel.The short-term efficacy and safety of the patients were observed.Results The therapeutic effects of 20 patients were evaluated.Among them,4 cases were partial response(PR),13 patients were stable disease(SD),3 patients were progressive disease(PD).The objective remission rate(ORR)was 20.0%,the disease control rate(DCR)was 85.0%,the median PFS(mPFS)was 4.5 months.The main adverse reactions were hypertension,vomiting and weakness.Conclusion Apatinib combined with docetaxel applied in the second-line treatment of gastric cancer is safe and effective.

关 键 词：胃肿瘤 阿帕替尼 多西他赛 二线治疗 

分 类 号：R735.2[医药卫生—肿瘤]